구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Bispecific antibodies (bsAB) |
Overview Company | Akeso |
Overview Modality | ANTIBODY |
Overview Target | Cancer |
Overview Indication | Cancer |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
MoA Mechanism | targets, such as CD98hc or transferrin receptor |
MoA Biomarker | PD-L1 (programmed death-ligand 1)-positive |
PK/PD Half-life | 51.9 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Bispecific antibodies: current advances and future perspectives.. Bispecific antibodies (BsAbs) are emerging immunotherapeutics that simultaneously engage two distinct targets. This property provides unique mechanisms of action that are not achieved by conventional monoclonal antibodies, including cell-cell bridging, modulation of multiple signaling pathways, and recruitment of diverse immune effe… |
Toxicology CRS | Reported |
Clinical Safety signal | Bispecific antibodies: current advances and future perspectives.. Bispecific antibodies (BsAbs) are emerging immunotherapeutics that simultaneously engage two distinct targets. This property provides unique mechanisms of action that are not achieved by conventional monoclonal antibodies, including cell-cell bridging, modulation of multiple signaling pathways, and recruitment of diverse immune effe… |
Clinical Selected reported efficacy | ORR 11.1% |
Clinical Reported ORR | 11.1% |
Clinical Result source | ClinicalTrials.gov NCT03340766 |
Clinical Program phase | PRECLINICAL |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT03340766 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Bispecific antibodies (bsAB) |
Overview Company | Akeso |
Overview Modality | ANTIBODY |
Overview Target | Cancer |
Overview Indication | Cancer |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
MoA Mechanism | targets, such as CD98hc or transferrin receptor |
MoA Biomarker | PD-L1 (programmed death-ligand 1)-positive |
PK/PD Half-life | 51.9 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Bispecific antibodies: current advances and future perspectives.. Bispecific antibodies (BsAbs) are emerging immunotherapeutics that simultaneously engage two distinct targets. This property provides unique mechanisms of action that are not achieved by conventional monoclonal antibodies, including cell-cell bridging, modulation of multiple signaling pathways, and recruitment of diverse immune effe… |
Toxicology CRS | Reported |
Clinical Safety signal | Bispecific antibodies: current advances and future perspectives.. Bispecific antibodies (BsAbs) are emerging immunotherapeutics that simultaneously engage two distinct targets. This property provides unique mechanisms of action that are not achieved by conventional monoclonal antibodies, including cell-cell bridging, modulation of multiple signaling pathways, and recruitment of diverse immune effe… |
Clinical Selected reported efficacy | ORR 11.1% |
Clinical Reported ORR | 11.1% |
Clinical Result source | ClinicalTrials.gov NCT03340766 |
Clinical Program phase | PRECLINICAL |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT03340766 |
추천 비교
추천 비교